PLEASANTON, Calif., Jan. 4, 2011 /PRNewswire/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11.
Gary F. Burbach, president and chief executive officer, will provide an update on the company, beginning at 4:30 p.m., Pacific Standard Time (7:30 p.m., Eastern Standard Time).
The presentation will be available through the conference web site at http://jpmorgan.metameetings.com/webcasts/healthcare11/directlink?ticker=THOR, or on the company's web site at http://www.thoratec.com.
Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's products include the HeartMate® LVAS (Left Ventricular Assist System) and Thoratec® VAD (Ventricular Assist Device) with more than 15,000 devices implanted in patients suffering from heart failure. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web site at http://www.thoratec.com.
Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered trademarks of Thoratec Corporation and IVAD is a trademark of Thoratec Corporation.
|SOURCE Thoratec Corporation|
Copyright©2010 PR Newswire.
All rights reserved